20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
AgomAb Therapeutics NV American Depositary Shares (AGMB) operates in the BIOTECHNOLOGY industry and is headquartered in Antwerp, Belgium with about 62 employees. Its market capitalization is roughly $369 million. In the fiscal year ended 2025-12-31, AGMB reported €0M in revenue and (€63M) in net income.
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States.
Interactive charts & full statements →
| Income statement | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue | — | €0M | €0M | €0M | €0M |
| Gross Profit | — | €0M | — | — | — |
| Gross Margin % | — | — | — | — | — |
| Operating Income (EBIT) | (€56M) | (€59M) | (€48M) | (€31M) | (€23M) |
| Operating Margin % | — | — | — | — | — |
| Net Income | (€59M) | (€63M) | (€46M) | (€11M) | (€8M) |
| Net Margin % | — | — | — | — | — |
| EBITDA | (€59M) | (€62M) | (€46M) | (€12M) | (€11M) |
| Earnings Per Share (EPS) | €-1.43 | €-1.28 | €-1.28 | €-0.31 | €-0.22 |
| Shares Outstanding (M) | 49M | 49M | 36M | 36M | 36M |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2024-12-31 |
|---|---|---|---|---|
| Total Revenue | — | €0M | €0M | €0M |
| Gross Profit | — | — | — | — |
| Operating Income (EBIT) | (€12M) | (€17M) | (€15M) | (€12M) |
| Operating Margin % | — | — | — | — |
| Net Income | (€12M) | (€17M) | (€18M) | (€12M) |
| Net Margin % | — | — | — | — |
| EBITDA | (€12M) | (€18M) | (€18M) | (€12M) |
| Earnings Per Share (EPS) | €-0.32 | €-0.36 | €-0.43 | €-0.32 |
| Shares Outstanding (M) | 36M | 49M | 42M | 36M |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Cash from Operations (CFO) | (€52M) | (€52M) | (€47M) | (€25M) | (€19M) |
| Capital Expenditures (CapEx) | €1M | €0M | €1M | €0M | €0M |
| Free Cash Flow (FCF) | (€52M) | (€52M) | (€48M) | (€25M) | (€19M) |
| FCF Margin % | — | — | — | — | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2024-12-31 |
|---|---|---|---|---|
| Cash from Operations (CFO) | (€12M) | (€13M) | (€14M) | (€12M) |
| Capital Expenditures (CapEx) | €0M | €0M | €0M | €0M |
| Free Cash Flow (FCF) | (€13M) | (€13M) | (€14M) | (€13M) |
| FCF Margin % | — | — | — | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Total Assets | €291M | €154M | €206M | €171M | €101M | €84M |
| Cash & Cash Equivalents | €222M | €86M | €171M | €122M | €28M | €54M |
| Total Liabilities | €26M | €23M | €18M | €20M | €35M | €42M |
| Total Debt (Short + Long-Term) | €0M | €0M | €0M | €0M | €0M | €1M |
| Total Shareholders' Equity | €265M | €131M | €188M | €151M | €66M | €42M |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AGMB viewer.
About TickerBase · Data methodology & sources · Privacy · Terms